Chile

Key Insights

1
No psychedelic therapy is approved in Chile; patients’ current legal option is off-label ketamine under medical supervision, not psilocybin or MDMA.
2
Blossom’s Chile dataset shows 1 clinical trial, 0 active, 1 research organisation, and ketamine as the only compound studied.
3
Chile’s psychedelic milestone is ketamine-led rather than classic psychedelic: the national research footprint is a single, isolated study, not a programme.
4
Momentum is thin but measurable: one institution anchors the field, and any expansion will likely come from psychiatry or anaesthesia rather than a dedicated psychedelic policy shift.

Medical Only (Private)

Reimbursed Care Access

Chile maintains a controlled-substances regulatory framework (Ley N°20.000) that generally classifies classical psychedelic compounds (psilocybin, MDMA, DMT, mescaline, 2C-series, 5‑MeO‑DMT, ibogaine) as controlled, with no routine public reimbursement outside authorized research. Ketamine is a registered anesthetic and is widely used clinically (including growing private-sector off‑label psychiatric programs); esketamine (Spravato) has a commercial registration and is available under medical supervision but access and public reimbursement are limited and largely handled in private settings.

Full guide →